TransCode Therapeutics is selling 10 million shares of its common stock for 30 cents each. This has it expecting to raise gross proceeds of $30 million from the public offering of RNAZ stock.

TransCode Therapeutics shares are trading lower by 16% during Monday's session. The company announced a 1-for-33 reverse stock split. Unlock your all-in-one trading dashboard with real-time alerts ...

BOSTON - TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a micro-cap RNA oncology company with a market capitalization of $6.22 ...

BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

Fintel reports that on August 15, 2023, HC Wainwright & Co. reiterated coverage of TransCode Therapeutics (NASDAQ:RNAZ) with a Buy recommendation. As of August 2, 2023, the average one-year price ...

TransCode Therapeutics (NASDAQ:RNAZ) stock is taking a beating on Tuesday after the biopharmaceutical company announced the pricing for a public offering of its shares. TransCode Therapeutics is ...